Inspire Medical Systems, Inc. (NYSE:INSP) Stock Has Average Price Target of $68.82

Key Points

• Analysts have a consensus “Hold” rating on Inspire Medical Systems, with 12 hold, four sell, three buy, and one strong-buy ratings. The average 12-month price target is $68.82, below the stock’s quoted price of $71.09.
• Inspire reported quarterly EPS of $0.14, beating the $0.24-per-share loss analysts expected, while revenue of $200.6 million exceeded estimates but declined 7.6% year over year.
• Institutional investors own 94.91% of the company, with several major funds increasing their positions; meanwhile, an insider sold 963 shares worth approximately $57,347.

Shares of Inspire Medical Systems, Inc. (NYSE:INSP - Get Free Report) have been given a consensus recommendation of "Hold" by the twenty analysts that are currently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $68.82.

A number of brokerages have issued reports on INSP. Evercore set a $54.00 target price on Inspire Medical Systems in a research report on Tuesday, August 4th. Stifel Nicolaus lifted their price objective on shares of Inspire Medical Systems from $75.00 to $80.00 and gave the company a "buy" rating in a research note on Friday, September 11th. Piper Sandler increased their price objective on shares of Inspire Medical Systems from $55.00 to $60.00 and gave the company a "neutral" rating in a report on Tuesday, August 4th. KeyCorp reiterated a "sector weight" rating on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. Finally, Freedom Capital upgraded Inspire Medical Systems to a "strong-buy" rating in a research report on Tuesday, June 30th.

Inspire Medical Systems Stock Performance

NYSE INSP opened at $71.09 on Monday. Inspire Medical Systems has a one year low of $38.91 and a one year high of $147.03. The company's 50 day moving average price is $67.54 and its 200 day moving average price is $55.44. The firm has a market capitalization of $2.06 billion, a price-to-earnings ratio of 15.39, a PEG ratio of 5.38 and a beta of 0.73.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its earnings results on Monday, August 3rd. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.38. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The business had revenue of $200.58 million for the quarter, compared to analyst estimates of $194.72 million. During the same quarter in the previous year, the business posted $0.45 EPS. The business's quarterly revenue was down 7.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. Sell-side analysts forecast that Inspire Medical Systems will post 1.24 EPS for the current fiscal year.

Insider Buying and Selling at Inspire Medical Systems

In other news, insider Jason Kelly sold 963 shares of Inspire Medical Systems stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $59.55, for a total value of $57,346.65. Following the transaction, the insider owned 18,985 shares of the company's stock, valued at $1,130,556.75. The trade was a 4.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 2.20% of the company's stock.

Institutional Trading of Inspire Medical Systems

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in shares of Inspire Medical Systems in the 2nd quarter worth $211,341,000. Assenagon Asset Management S.A. lifted its holdings in shares of Inspire Medical Systems by 66.2% during the second quarter. Assenagon Asset Management S.A. now owns 864,395 shares of the company's stock valued at $38,561,000 after purchasing an additional 344,221 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Inspire Medical Systems by 21.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 546,020 shares of the company's stock valued at $24,358,000 after purchasing an additional 97,233 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Inspire Medical Systems by 14.4% during the first quarter. Renaissance Technologies LLC now owns 469,968 shares of the company's stock valued at $24,241,000 after purchasing an additional 59,200 shares during the last quarter. Finally, ADAR1 Capital Management LLC boosted its position in shares of Inspire Medical Systems by 2,601.3% in the 1st quarter. ADAR1 Capital Management LLC now owns 405,197 shares of the company's stock valued at $20,900,000 after purchasing an additional 390,197 shares during the period. 94.91% of the stock is owned by institutional investors and hedge funds.

About Inspire Medical Systems

Inspire Medical Systems, Inc develops and commercializes medical devices for the treatment of obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly narrows or becomes blocked during sleep. The company's primary product is Inspire therapy, an implantable system designed to help keep the airway open by stimulating the hypoglossal nerve, which controls muscles involved in maintaining airway patency.

Inspire therapy is intended for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.